Experimental antibody may boost leukemia treatment
NCT ID NCT06384261
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether adding an experimental antibody called cusatuzumab to the standard drugs venetoclax and azacitidine helps people with newly diagnosed acute myeloid leukemia (AML) live longer. The study includes 140 adults who cannot have intensive chemotherapy. Participants are randomly assigned to receive either the three-drug combination or the standard two drugs alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cusatuzumab (an experimental antibody) added to venetoclax and azacitidine
What this could lead to
If it works, this could lead to a new treatment option that helps people with AML live longer without needing intensive chemotherapy.
What could go wrong
This is an early phase 2 trial with only 140 participants, so results may not apply to everyone. Adding cusatuzumab could also increase side effects without improving survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA, MYELOID, ACUTE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AdventHealth Medical Group Blood & Marrow Transplant at Orlando
Orlando, Florida, 32804, United States
-
Banner MD Anderson
Gilbert, Arizona, 85234, United States
-
City of Hope
Duarte, California, 91010, United States
-
Cleveland Clinic - Taussig Cancer Institute
Cleveland, Ohio, 44195, United States
-
Cornell University
New York, New York, 10065, United States
-
Fred Hutch Seattle Cancer Care Alliance
Seattle, Washington, 98109, United States
-
HFR Fribourg - Hopital Cantonal
Fribourg, Switzerland, Switzerland
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Hofstra/Northwell Health
Lake Success, New York, 11042, United States
-
Hospital De La Santa
Barcelona, Spain
-
Hospital Universitario de Salamanca
Salamanca, Spain
-
Inselspital Bern
Bern, 3010, Switzerland
-
Instituto Catalan de Oncologia - Hospital Duran i Reynals
Barcelona, Spain
-
Kantonsspital St. Gallen
Sankt Gallen, 9007, Switzerland
-
Marien Hospital Duesseldorf
Düsseldorf, 40479, Germany
-
Medical College of Wisonsin
Milwaukee, Wisconsin, 53226, United States
-
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
-
Norton Healthcare, Inc.
Louisville, Kentucky, 40202, United States
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5F 2M9, Canada
-
Saskatchewan Cancer Agency - Saskatoon Cancer Centre
Saskatoon, Saskatchewan, S7N4H4, Canada
-
Stollery Children's Hospital-Walter C Mackenzie Health Sciences Centre - University of Alberta
Edmonton, Alberta, T6G 2B7, Canada
-
The Ottawa Hospital - General Campus
Ottawa, Ontario, K1H8L6, Canada
-
The University of Iowa Hospitals & Clinics
Iowa City, Iowa, 52242, United States
-
Tom Baker Cancer Center-Alberta Health Services - University of Calgary
Calgary, Alberta, T2N 4N2, Canada
-
Universidad de Navarra - Clinica Universidad de Navarra
Pamplona, Spain
-
Universitaetsklinik Frankfurt
Frankfurt, 60560, Germany
-
Universitaetsklinik um Schleswig-Holstein, UKSH-Campus Kiel
Kiel, 24105, Germany
-
University of California Los Angeles
Los Angeles, California, 90095, United States
-
University of Colorado Health - Anschutz Cancer Pavilion - Anschutz Medical Campus
Aurora, Colorado, 80045, United States
-
University of Kentucky Chandler Medical Center
Lexington, Kentucky, 40536, United States
-
University of Miami - Sylvester Comprehensive Cancer Center - Miami
Miami, Florida, 33136, United States
-
University of Rochester Medical Center
Rochester, New York, 14642, United States
-
University of South Florida = Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
-
University of Western Ontario
London, Ontario, N6A5W9, Canada
-
Vall d'Hebron Institute of Oncology
Barcelona, Spain
-
Vancouver General Hospital, Gordon and Leslie Diamond Health Care Centre
Vancouver, British Columbia, V5Z 1M9, Canada
-
Wake Forest North Carolina
Winston-Salem, North Carolina, 27157, United States
-
Yale School of Medicine
New Haven, Connecticut, 06510, United States